Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
1,274 total articles
SurgePays, a wireless and fintech technology company serving subprime and underserved consumers, announced the launch of a customizable stored value and loyalty platform for merchants nationwide. Integrated into its point-of-sale platform, this new offering enables merchants to operate branded gift cards, store credits, and loyalty programs seamles…
Intelligent Bio Solutions Inc. successfully completed its initial clinical Cut-off Study for its Intelligent Fingerprinting Drug Screening System detecting opiate codeine, progressing its FDA 510(k) submission process. The company has initiated the second phase clinical studies, including Method Comparison, Usability, and Interference Testing, targ…
Fiserv, Inc. released its March 2026 Small Business Index indicating steady growth in U.S. small business sales, supported by higher average ticket sizes which offset slower foot traffic. The data highlights cautious consumer behavior influenced by rising energy prices, with increased spending at gasoline stations but moderated restaurant and groce…
Abeona Therapeutics has announced the activation of NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center for administering ZEVASKYN, a gene-modified cellular therapy for recessive dystrophic epidermolysis bullosa (RDEB). This expansion significantly improves patient access to this novel therapy in t…
Ultragenyx announced the FDA’s acceptance of the resubmitted Biologics License Application for UX111, an AAV9 gene therapy targeting Sanfilippo syndrome Type A (MPS IIIA), a rare and fatal neurodegenerative disease in children. The FDA granted Priority Review with an expected decision date of September 19, 2026. Clinical data show durable treatment…
CSW Industrials announced an 11% increase in its quarterly dividend to $0.30 per share and repurchased approximately $35 million in shares during the fiscal fourth quarter of 2026. The company highlighted its strong balance sheet, consistent cash flow, and profitability, supporting continued capital return strategies including dividends and share b…
NewAmsterdam Pharma, a clinical-stage biopharmaceutical company focused on developing oral, non-statin LDL cholesterol-lowering therapies, announced inducement share options and restricted stock units granted to two new non-executive employees as part of its 2024 Inducement Plan. The grants comply with Nasdaq Listing Rule 5635(c)(4) and vest over t…
Merit Medical Systems, a global healthcare technology company specializing in proprietary medical devices, will release its financial results for Q1 2026 after market close on April 30, 2026, followed by an investor conference call.
Toro Corp., a NASDAQ-listed global energy transportation services provider, announced a $60 million revolving credit facility with a leading European financial institution. The five-year facility will be secured by a first priority mortgage on four of the Company's vessels, with proceeds earmarked for general corporate use.
MiMedx Group, Inc. announced its sponsorship and active participation in two leading wound care conferences—SAWC Spring 2026 and MedStar Georgetown's Diabetic Limb Salvage Conference. The company will highlight its expanded advanced wound care portfolio and present new scientific data, emphasizing clinical evidence and innovative treatments geared …
FinWise Bancorp, a US-based bank specializing in fintech banking and payments solutions, has scheduled its first quarter 2026 earnings release and conference call for April 30, 2026. The company enables fintech brands with scalable API-driven lending and payments programs and is expanding its services to include payments and BIN sponsorship offerin…
Riverview Bancorp, a community bank headquartered in Vancouver, Washington, has appointed Kourosh Zamani and Jon Girod to its board of directors. Zamani brings expertise in AI-driven technology and entrepreneurial experience, while Girod offers decades of home building and development experience in the Pacific Northwest. Their additions aim to enha…
Primech Holdings Limited, a Nasdaq-listed company, announced that its subsidiary, Primech A & P, has secured a US$24 million contract to deliver integrated cleaning services across six prominent hawker and food centres in Singapore. The 4+1-year performance-based contract emphasizes technology-driven operational efficiencies including automation an…
IP Strategy Holdings, Inc. (NASDAQ: IPST) provided its monthly update highlighting its validator operations on the Story blockchain network. Since launching in September 2025, the company's validator has demonstrated near-perfect uptime and transitioned to a long-term staking model, expected to increase yields. For March 2026, the company earned ov…
Minerals Technologies Inc. will release its first quarter 2026 financial results after market close on April 30, 2026, followed by a conference call on May 1 to discuss these results. The company provides specialty mineral products worldwide and reported $2.1 billion in sales for 2025.
BioCardia has submitted clinical data to the FDA and requested a meeting under the FDA's Breakthrough Designation to discuss accelerated approval of its CardiAMP System for treating ischemic heart failure with reduced ejection fraction. The CardiAMP HF Trial demonstrated significant clinical benefits in a high-risk patient subgroup, including subst…
LKQ Corporation will report its financial results for Q1 2026 on April 30, followed by a detailed conference call and webcast led by senior management. The company operates internationally, providing alternative and specialty vehicle parts, with investor access facilitated through multiple communication channels.
Daktronics, a leading US-based designer and manufacturer of dynamic video displays and control systems, will ring the Nasdaq Closing Bell on April 8, 2026, marking a milestone event shortly after announcing its fiscal third quarter results and ahead of its Investor Day. The event symbolizes Daktronics' focus on accelerating profitable growth and ce…
First Merchants Corporation, a financial holding company based in Muncie, Indiana, will report its first quarter 2026 financial results on April 22, 2026. The company will host a conference call and webcast on April 23, 2026, to discuss the results. The stock is traded on NASDAQ under the ticker symbol FRME.
Celldex Therapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering of 10,345,000 shares at $29.00 per share, expecting gross proceeds of approximately $300 million. The offering aims to fund its commercial readiness and potential launch of barzolvolimab for chronic spontaneous urticaria, continue …
Telesat Corporation announced a significant multi-year agreement with Northwestel to provide advanced Lightspeed Low Earth Orbit (LEO) satellite services. This deal aims to deliver high-speed, low-latency sovereign broadband to remote communities in Northern Canada, supporting economic growth, education, healthcare, and broader digital participatio…
Immunovant announced that its Phase 3 clinical trials for batoclimab in treating thyroid eye disease (TED) failed to meet their primary efficacy endpoint. While safety profiles were consistent with previous results and no new risks identified, the drug did not achieve the targeted proptosis improvement at 24 weeks. The company highlighted promising…
Futu Holdings Limited, a Nasdaq-listed online brokerage and wealth management platform, declared a cash dividend of $0.325 per ordinary share (equivalent to $2.6 per American Depositary Share), totaling approximately $365 million, payable to shareholders as of April 16, 2026, with payment expected around April 29, 2026.
Priovant Therapeutics announced the initiation of a seamless Phase 2b/3 clinical trial for brepocitinib in treating Lichen Planopilaris (LPP), a severe inflammatory scalp disorder with no FDA-approved treatments. This marks the fourth indication in brepocitinib's late-stage development alongside dermatomyositis, non-infectious uveitis, and cutaneou…
Roivant Sciences announced the expansion of its brepocitinib development program to include a new seamless Phase 2b/3 clinical trial for the inflammatory scalp disorder lichen planopilaris (LPP), which currently has no FDA-approved treatments. Concurrently, Roivant reported topline results from Immunovant's Phase 3 studies of batoclimab in thyroid …
